Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
cAMeLot-2: Bleximenib + Venetoclax + Azacitidine in Newly Diagnosed AML with KMT2A Rearrangements or NPM1 Mutations Ineligible for Intensive Chemotherapy
jRCT2051250029Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2025
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of bleximenib in acute myeloid leukemia (AML) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Complete remission rate and Overall survival. Started Sep 2025; status: recruiting.
02
Drugs
bleximenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on jRCT2051250029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051250029.